 |
|||
 |
 |
||
 |
|||
 |
|||
 |
 |
||
 |
|||
 |
|||
 |
 |
 |
|
 |
|||
 |
|
|
|
November, 2009
Important research about the feasibility of self-managed monitoring technology to improve Health Outcomes, the "Diabetes and Technology for Increased Activity" or DaTA Study was presented at the Diabetes Technology meeting, San Francisco, CA. Click on the link to view the abstract: Diabetes Technology Meeting Nov 2009
October 23, 2009
Results of a pilot study to determine the feasibility of remote monitoring to modify lifestyle in pre-diabetic patients, with limited access to preventative care, were presented at the Canadian Association of Cardiac Rehabilitation Annual meeting. To view the abstract: DaTA Cdn Association Cardiac Rehab Oct 09
October 8, 2009
At the Ontario Ministry of Health and Long Term Care Health Research Showcase meeting, a poster about the Diabetes and Technology for Increased Activity (DaTA) Study was presented. Click on the link to view the poster. DaTA Study Poster October 2009
September, 2009
Diabetes and Technology for Increased Activity (DaTA) Study abstract accepted for presentation at the American Telemedicine Association conference. To read the abstract click on the link: American Telemedicine Assoc. Sept 2009
June 2007
Research regarding Clinical and Cardiovascular Research in Latin America and the Caribbean was published in Prevention and Control, the journal of the World Health Federation. The manuscript is entitled "Trends, challenges and promotion of clinical and cardiovascular research in Latin America and the Caribbean" and explores cardiovascular and clinical research output in these countries, the momentum toward public and private sector partnerships as well as the rationale for lack of progress in overcoming the burden of cardiovascular disease in the region. Prevention and Control. 2006;2:129-135. Link to manuscript: PRECON
April 2007
Important research findings regarding the patient-borne costs of diabetes were published in the Canadian Journal of Diabetes, March 2007. Katalyst Health Technology Assessments provided clinical trial coordination and management for the multi-centre study. This Canadian study measured the costs associated with the control of blood glucose levels. Katalyst facilitated the analyses of the study findings. The publication provides data confirming the significant costs of managing blood glucose for people with type 1 diabetes and insulin-treated type 2 diabetes. Can J Diabetes. 2007;31(1):25-33. To read the paper click on the link: Cost_HperHypoFeb232007
2006
A manuscript exploring opportunities and challenges for clinical research in Latin America was published in the American Journal of Therapeutics. The paper, "Opportunities and Challenges for Clinical and Cardiovascular Research in Latin America" investigates the increasingly significant contributions of Latin America to clinical and specifically cardiovascular research. Am Jrnl of Therapeutics. 2006;13(4):309-314.
March 2005
"Assessment of the Impact of Fear of Hypoglycemic Episodes on Glycemic and Hypoglycemia Management" was published in the Canadian Journal of Diabetes. This manuscript explores the fear and impact of hypoglycemia on type 1 and insulin treated type 2 diabetes patients. Can J Diabetes. 2005;29(3):186-192. To read the paper click on the link: Leiter_Hypo-pages186-192
February 2005
Public Awareness of Hypertension research study published in the American Journal of Hypertension. The results of a social marketing campaign to raise awareness of hypertension was conducted by Katalyst in conjunction with Dr. Robert Petrella, Dr. Mark Speechley and Blood Pressure Canada. The paper, "Impact of a Social Marketing Media Campaign on Public Awareness of Hypertension" provides unique insight into the barriers to high blood pressure awareness and control. AJH 2005;18:270-275.
Read More >>
KatalystTM Health Technology Assessments is pleased
to announce that the abstract entitled “PHARMACEUTICAL
LIFE CYCLE MODELS BY THERAPEUTIC CATEGORY”, authored
by Dr. Mark Speechley (Epidemiology and Biostatistics,
University of Western Ontario) and Dr. Peter Kleinstiver
(Katalyst), has been accepted for presentation at the
ISTAHC 2003 conference in June 2003.
Read More >>.
December 2003 Read
Abstract...
KatalystTM
Health Technology Assessments is pleased to announce that they have received
an Industrial Research Assistance Program (IRAP) award valued at over
$90,000. The grant, obtained through the National Research Council program,
will provide funding for research and development of the next version
of PhORECASTTM-Rx, a budget impact analysis software program.
June 2003
Katalyst Health Technology Assessments is pleased to announce that the abstract entitled “PHARMACEUTICAL LIFE CYCLE MODELS BY THERAPEUTIC CATEGORY”, authored by Dr. Mark Speechley (Epidemiology and Biostatistics, University of Western Ontario) and Dr. Peter Kleinstiver (Katalyst), has been accepted for presentation at the ISTAHC 2003 conference in June 2003. Link to AbstractREa
May 2003
Katalyst
Health Technology Assessments presented a poster “Does the Past
Predict the Future?” at the 8th Annual International meeting of
the International Society for Pharmacoeconomics and Outcomes Research
(ISPOR), in Arlington, Virginia. This research will be developed into
a predictive algorithm and incorporated into PhORECAST-RxTM, a proprietary
and unique model developed by Katalyst to automate the forecasting process
and allow the user to more accurately predict budget impact associated
with adding a new product onto a closed formulary.
21/05/02 Read
Abstract...
February
22, 2002. Katalyst Health Technology Assessments has had an abstract accepted
for a Workshop Presentation at the International Society for Pharmacoeconomics
and Outcomes Research (ISPOR) 7th Annual International Meeting, May 19-22,
2002 at the Hyatt Regency Crystal City in Arlington, Virginia. COMPARISON
OF "TOP-DOWN" VS "BOTTOM-UP" BUDGET IMPACT MODELS.
01/02/02
February 1,
2002. Katalyst Health Technology Assessments is pleased to announce the
successful funding of a Canada Foundation for Innovation grant for a state-of
the-art animal care facility at the University of Western Ontario. CFI
announced on January 31, 2002 that almost $14 Million dollars will be
committed to funding the London Regional Innovarium. The Innovarium is
a partnership between the University of Western Ontario, the Lawson Health
Research Institute and The John P. Robarts Research Institute and is valued
at $34.5 million dollars.Katalyst is proud to have written the CFI grant
for the Innovarium and is optimistic about growth for the internationally
recognized and innovative research programs in London and region.
18/11/01 Read Abstract...
Companies producing
innovative products typically terminate all advertising and promotion
(A&P) of branded products once generics have been launched. This may
be prudent since branded sales often decline 50%-75% in the first year
following generic introduction. Our primary hypothesis was that companies,
which cease A&P on products
about to be genericized, might indirectly hasten branded product sales
decline by increasing the relative share of competitors' promotional activity.
10/09/01
Peter Kleinstiver, President, Katalyst Health Technology Assessments has
been appointed to the Board of Directors of St. Joseph's Health Care London.
Peter is a member of the Canadian Health Economics Research organization,
the International Society for Pharmacoeconomics and Outcomes Research
and the Drug Information Association
15/08/00 Read Abstract...
Sandra Kleinstiver,
partner with Katalyst Health Technology Assessments, is the recipient
of the London Chamber of Commerce's President’s Award for Volunteer
Service. The Award
is given annually to a Chamber member for "service above and beyond
the call of duty".
12/08/99 Read
Article
Katalyst is pleased to announce publication of A Predictive Cost Analysis
Model for Estimating Formulary Impact of New Products in Managed Care
in the November/December issue of the Journal of Managed Care Pharmacy.